What is Trinity Biotech Plc's earnings per share (EPS)?

Trinity Biotech Plc (TRIB) reported diluted earnings per share of $-2.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Trinity Biotech Plc Financials

TRIB

Source SEC Filings (10-K/10-Q) Data as of Apr 30, 2026 Currency USD FYE April

This page shows Trinity Biotech Plc (TRIB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TRIB FY2025 2026-04-30

A brief accounting profit masks a business still running on external funding as cash generation and liquidity remain weak.

In FY2025, net income turned positive at $1.9M, but operating cash flow stayed at -$5.9M and free cash flow at -$6.0M; paired with the current ratio falling from 1.3x in FY2024 to 0.3x, that points to a profit figure lifted by non-cash items while near-term obligations became harder to cover.

The balance sheet is now creditor-dominated: total liabilities reached $177.1M against $105.2M of assets, and equity sank to -$72.0M. With $57.0M of goodwill on the asset side, a large share of reported assets is not liquid support for day-to-day funding.

Across FY2024-FY2025, the company generated negative operating cash flow in both years yet received $40.9M of financing cash inflows, showing that the operating model has not recently funded itself. That matters because revenue fell to $43.8M in FY2025 from $61.6M in FY2024, so the narrower loss profile did not come from a larger sales base.

Financial Health Signals

Financial Health Score 29/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Trinity Biotech Plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

Revenue Progress

Burn Trend

Balance Sheet

Piotroski F-Score Partial

2/7

Trinity Biotech Plc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

-3.10x

For every $1 of reported earnings, Trinity Biotech Plc generates $-3.10 in operating cash flow (-$5.9M OCF vs $1.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$43.8M

YoY-28.9%

5Y CAGR-15.6%

10Y CAGR-7.9%

Trinity Biotech Plc generated $43.8M in revenue in fiscal year 2025. This represents a decrease of 28.9% from the prior year.

EBITDA

N/A

Net Income

$1.9M

YoY+106.1%

10Y CAGR-21.7%

Trinity Biotech Plc reported $1.9M in net income in fiscal year 2025. This represents an increase of 106.1% from the prior year.

EPS (Diluted)

$-2.00

Trinity Biotech Plc earned $-2.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$6.0M

YoY-30.9%

Trinity Biotech Plc generated -$6.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 30.9% from the prior year.

Cash & Debt

$5.1M

YoY-0.6%

5Y CAGR-28.4%

10Y CAGR-25.8%

Trinity Biotech Plc held $5.1M in cash against $20.0M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

374M

YoY+4.2%

5Y CAGR+35.0%

Trinity Biotech Plc had 374M shares outstanding in fiscal year 2025. This represents an increase of 4.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

4.4%

YoY+55.1pp

5Y CAGR+10.3pp

10Y CAGR-17.8pp

Trinity Biotech Plc's net profit margin was 4.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 55.1 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$88K

YoY-78.3%

5Y CAGR-51.2%

10Y CAGR-35.5%

Trinity Biotech Plc invested $88K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 78.3% from the prior year.

TRIB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$43.8M-28.9%	$61.6M+8.3%	$56.8M-9.1%	$62.5M-23.0%	$81.1M-20.4%	$102.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$644K+8.8%	$592K-5.1%	$624K-3.6%	$647K-19.4%	$803K-10.4%	$896K
Income Tax	$199K-59.1%	$486K+923.7%	-$59K+69.6%	-$194K-162.2%	-$74K+88.1%	-$620K
Net Income	$1.9M+106.1%	-$31.2M+15.3%	-$36.9M+15.4%	-$43.6M-2256.0%	-$1.9M+69.2%	-$6.0M
EPS (Diluted)	$-2.00	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q3'23	Q1'23	Q3'22	Q3'21	Q3'20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TRIB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$105.2M+1.8%	$103.3M+73.8%	$59.4M-35.5%	$92.1M-22.5%	$118.9M-8.8%	$130.4M
Current Assets	$35.9M-12.7%	$41.1M+5.3%	$39.0M-16.3%	$46.7M-35.8%	$72.7M-12.7%	$83.3M
Cash & Equivalents	$5.1M-0.6%	$5.2M+40.0%	$3.7M-43.9%	$6.6M-74.6%	$25.9M-5.2%	$27.3M
Inventory	$18.8M-2.8%	$19.4M-2.8%	$19.9M-11.4%	$22.5M-22.7%	$29.1M-3.6%	$30.2M
Accounts Receivable	$11.5M-28.5%	$16.1M+15.6%	$13.9M-11.8%	$15.8M-2.3%	$16.1M-28.9%	$22.7M
Goodwill	$57.0M+11.0%	$51.3M+215.6%	$16.3M-53.9%	$35.3M-2.0%	$36.0M+6.3%	$33.9M
Total Liabilities	$177.1M+27.9%	$138.5M+66.1%	$83.4M-11.6%	$94.3M-20.9%	$119.2M-10.1%	$132.6M
Current Liabilities	$141.2M+340.0%	$32.1M+113.5%	$15.0M-13.3%	$17.3M-82.7%	$100.5M+271.4%	$27.1M
Long-Term Debt	$20.0M	N/A	$10.9M	N/A	$13.9M+1230.6%	$1.0M
Total Equity	-$72.0M-104.6%	-$35.2M-46.9%	-$23.9M-1000.6%	-$2.2M-582.1%	-$319K+85.6%	-$2.2M
Retained Earnings	-$116.2M-46.8%	-$79.1M-62.6%	-$48.6M-82.2%	-$26.7M-312.6%	$12.6M+18.8%	$10.6M

Metric	Q3'25	Q1'25	Q3'24	Q3'23	Q1'23	Q3'22	Q3'21	Q3'20
Total Assets	$103.3M+9.5%	$94.4M+58.8%	$59.4M-35.5%	$92.1M-14.0%	$107.1M-9.9%	$118.9M-8.8%	$130.4M-0.5%	$131.1M
Current Assets	$41.1M-10.6%	$46.0M+17.8%	$39.0M-16.3%	$46.7M-18.5%	$57.2M-21.3%	$72.7M-12.7%	$83.3M+16.7%	$71.4M
Cash & Equivalents	$5.2M-2.8%	$5.3M+44.1%	$3.7M-43.9%	$6.6M-37.1%	$10.5M-59.7%	$25.9M-5.2%	$27.3M+79.4%	$15.2M
Inventory	$19.4M-15.6%	$23.0M+15.2%	$19.9M-11.4%	$22.5M-22.7%	$29.1M0.0%	$29.1M-3.6%	$30.2M-5.6%	$32.0M
Accounts Receivable	$16.1M-8.0%	$17.5M+25.7%	$13.9M-11.8%	$15.8M-1.0%	$15.9M-1.3%	$16.1M-28.9%	$22.7M+8.0%	$21.0M
Goodwill	$51.3M+22.9%	$41.8M+156.8%	$16.3M-53.9%	$35.3M-9.0%	$38.7M+7.7%	$36.0M+6.3%	$33.9M-22.4%	$43.7M
Total Liabilities	$138.5M+11.9%	$123.8M+48.4%	$83.4M-11.6%	$94.3M+3.2%	$91.3M-23.4%	$119.2M-10.1%	$132.6M+5.0%	$126.4M
Current Liabilities	$32.1M+24.5%	$25.8M+71.4%	$15.0M-13.3%	$17.3M+24.9%	$13.9M-86.2%	$100.5M+271.4%	$27.1M+39.1%	$19.4M
Long-Term Debt	N/A	$10.2M-6.2%	$10.9M	N/A	$12.7M-8.2%	$13.9M+1230.6%	$1.0M0.0%	$1.0M
Total Equity	-$35.2M-19.7%	-$29.4M-22.8%	-$23.9M-1000.6%	-$2.2M-113.8%	$15.8M+5058.9%	-$319K+85.6%	-$2.2M-147.1%	$4.7M
Retained Earnings	-$79.1M-36.9%	-$57.8M-18.8%	-$48.6M-82.2%	-$26.7M-193.3%	-$9.1M-172.5%	$12.6M+18.8%	$10.6M-34.5%	$16.1M

TRIB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.9M-41.5%	-$4.2M+63.7%	-$11.6M-1154.8%	-$921K-107.0%	$13.2M-44.3%	$23.8M
Capital Expenditures	$88K-78.3%	$405K-49.6%	$803K-27.1%	$1.1M-39.2%	$1.8M-43.0%	$3.2M
Free Cash Flow	-$6.0M-30.9%	-$4.6M+62.8%	-$12.4M-511.3%	-$2.0M-117.7%	$11.4M-44.5%	$20.6M
Investing Cash Flow	-$6.2M+72.9%	-$23.0M-192.8%	$24.8M+514.2%	-$6.0M+31.2%	-$8.7M+14.8%	-$10.2M
Financing Cash Flow	$12.1M-58.2%	$28.8M+279.6%	-$16.0M-30.2%	-$12.3M-104.7%	-$6.0M-121.6%	-$2.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q1'25	Q3'24	Q3'23	Q1'23	Q3'22	Q3'21	Q3'20
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TRIB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	4.4%+55.1pp	-50.7%+14.2pp	-64.9%+4.8pp	-69.7%-67.4pp	-2.3%+3.6pp	-5.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	1.8%+32.0pp	-30.2%+31.8pp	-62.0%-14.7pp	-47.3%-45.8pp	-1.6%+3.1pp	-4.6%
Current Ratio	0.25-1.0	1.28-1.3	2.60-0.1	2.69+2.0	0.72-2.4	3.08
Debt-to-Equity	-0.28+3.7	-3.94-3.5	-0.45+42.9	-43.33+0.1	-43.46-43.0	-0.47
FCF Margin	-13.7%-6.3pp	-7.5%+14.3pp	-21.8%-18.5pp	-3.2%-17.3pp	14.1%-6.1pp	20.2%

Metric	Q3'25	Q1'25	Q3'24	Q3'23	Q1'23	Q3'22	Q3'21	Q3'20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.28-0.5	1.78-0.8	2.60-0.1	2.69-1.4	4.12+3.4	0.72-2.4	3.08-0.6	3.67
Debt-to-Equity	-3.94-3.6	-0.35+0.1	-0.45+42.9	-43.33-44.1	0.80+44.3	-43.46-43.0	-0.47-0.7	0.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$72.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.25), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

$19.5M

$40.6M

$12.6M

$15.4M

$14.1M

Frequently Asked Questions

What is Trinity Biotech Plc's annual revenue?

Trinity Biotech Plc (TRIB) reported $43.8M in total revenue for fiscal year 2025. This represents a -28.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Trinity Biotech Plc's revenue growing?

Trinity Biotech Plc (TRIB) revenue declined by 28.9% year-over-year, from $61.6M to $43.8M in fiscal year 2025.

Is Trinity Biotech Plc profitable?

Yes, Trinity Biotech Plc (TRIB) reported a net income of $1.9M in fiscal year 2025, with a net profit margin of 4.4%.

How much debt does Trinity Biotech Plc have?

As of fiscal year 2025, Trinity Biotech Plc (TRIB) had $5.1M in cash and equivalents against $20.0M in long-term debt.

What is Trinity Biotech Plc's net profit margin?

Trinity Biotech Plc (TRIB) had a net profit margin of 4.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Trinity Biotech Plc's free cash flow?

Trinity Biotech Plc (TRIB) generated -$6.0M in free cash flow during fiscal year 2025. This represents a -30.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Trinity Biotech Plc's operating cash flow?

Trinity Biotech Plc (TRIB) generated -$5.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Trinity Biotech Plc's total assets?

Trinity Biotech Plc (TRIB) had $105.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Trinity Biotech Plc's capital expenditures?

Trinity Biotech Plc (TRIB) invested $88K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Trinity Biotech Plc have outstanding?

Trinity Biotech Plc (TRIB) had 374M shares outstanding as of fiscal year 2025.

What is Trinity Biotech Plc's current ratio?

Trinity Biotech Plc (TRIB) had a current ratio of 0.25 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Trinity Biotech Plc's debt-to-equity ratio?

Trinity Biotech Plc (TRIB) had a debt-to-equity ratio of -0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Trinity Biotech Plc's return on assets (ROA)?

Trinity Biotech Plc (TRIB) had a return on assets of 1.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Trinity Biotech Plc's cash runway?

Based on fiscal year 2025 data, Trinity Biotech Plc (TRIB) had $5.1M in cash against an annual operating cash burn of $5.9M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Trinity Biotech Plc's debt-to-equity ratio negative or unusual?

Trinity Biotech Plc (TRIB) has negative shareholder equity of -$72.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Trinity Biotech Plc's Piotroski F-Score?

Trinity Biotech Plc (TRIB) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Trinity Biotech Plc's earnings high quality?

Trinity Biotech Plc (TRIB) has an earnings quality ratio of -3.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Trinity Biotech Plc?

Trinity Biotech Plc (TRIB) scores 29 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.